{"id":16805,"date":"2024-12-19T17:17:20","date_gmt":"2024-12-19T16:17:20","guid":{"rendered":"https:\/\/www.ifpma.org\/?post_type=publications&#038;p=16805"},"modified":"2025-11-04T16:08:46","modified_gmt":"2025-11-04T15:08:46","slug":"global-regulatory-approaches-to-post-approval-changes-in-biotherapeutic-products","status":"publish","type":"publications","link":"https:\/\/www.ifpma.org\/publications\/global-regulatory-approaches-to-post-approval-changes-in-biotherapeutic-products\/","title":{"rendered":"Global regulatory approaches to post-approval changes in biotherapeutic products"},"content":{"rendered":"<p class=\"intro\">In 2024, IFPMA worked with Clarivate to study how different countries and regions approach the regulation of post-approval changes (PACs) in biotherapeutic products.<\/p>\n<p>The research compared PACs guidelines across 21 countries and regions in Latin America (LATAM), Asia-Pacific (APAC), and the Middle East and Africa (MEA) to the World Health Organization (WHO) <a href=\"https:\/\/che01.safelinks.protection.outlook.com\/?url=https%3A%2F%2Fwww.who.int%2Fpublications%2Fm%2Fitem%2Fapproved-biotherapeutics-a3-trs-no-1011&amp;data=05%7C02%7Cam.nia%40ifpma.org%7Cfe1038f2198c487baac508dd2023c87e%7C40da4b52beac45b3b642e76de9ecf24c%7C0%7C0%7C638702060258380774%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&amp;sdata=zVkHOPQ8pUciYUARrsbx1JY9D1NjPgTRioPXmONR7ps%3D&amp;reserved=0\">Guidelines on changes on biotherapeutic products.<\/a><\/p>\n<p>In October 2025, the study was updated to include an analysis of the EU PACs Guideline, issued in 2025, described in detail in Annex 1 of this publication.<\/p>\n<p>The findings reveal significant diversity in the level of convergence among countries and with the WHO, with a few notable trends.<\/p>\n<h5>Key recommendations<\/h5>\n<ul>\n<li>Global regulatory convergence using a science and risk-based regulatory framework enables more efficient management of PACs, especially when specifically adapted to biologics (and other modalities)<\/li>\n<li>Establishing national or regional variation guidelines in line with international standards (e.g. WHO, ICH Q12) in terms of categorization, requirements and timelines allows predictability and consistency in the handling of changes without the need for additional local requirements<\/li>\n<li>Expanding reliance practices to include life cycle management will accelerate the approval of changes, facilitating patient access to innovative, high-quality, and safe products.<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>IFPMA worked with Clarivate to study how different countries regulate post-approval changes (PACs) in biotherapeutic products. The research compared PACs guidelines across 21 countries and regions in Latin America (LATAM), Asia-Pacific (APAC), and the Middle East and Africa (MEA) to the World Health Organization (WHO) Guidelines on changes on biotherapeutic products. The findings reveal significant diversity in the level of convergence among countries and with the WHO Reference Guidelines, with a few notable trends.<\/p>\n","protected":false},"featured_media":16806,"template":"","publication_type":[8],"topic":[28,26],"class_list":["post-16805","publications","type-publications","status-publish","has-post-thumbnail","hentry","publication_type-external-study","topic-biotherapeutics","topic-regulatory-convergence-and-reliance"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.3 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Global regulatory approaches to post-approval changes in biotherapeutic products | IFPMA<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ifpma.org\/publications\/global-regulatory-approaches-to-post-approval-changes-in-biotherapeutic-products\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Global regulatory approaches to post-approval changes in biotherapeutic products | IFPMA\" \/>\n<meta property=\"og:description\" content=\"IFPMA worked with Clarivate to study how different countries regulate post-approval changes (PACs) in biotherapeutic products. The research compared PACs guidelines across 21 countries and regions in Latin America (LATAM), Asia-Pacific (APAC), and the Middle East and Africa (MEA) to the World Health Organization (WHO) Guidelines on changes on biotherapeutic products. The findings reveal significant diversity in the level of convergence among countries and with the WHO Reference Guidelines, with a few notable trends.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ifpma.org\/publications\/global-regulatory-approaches-to-post-approval-changes-in-biotherapeutic-products\/\" \/>\n<meta property=\"og:site_name\" content=\"IFPMA\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/IFPMA\/\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-04T15:08:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.ifpma.org\/wp-content\/uploads\/2024\/12\/Copy-of-Publications-Portrait-cover.png\" \/>\n\t<meta property=\"og:image:width\" content=\"634\" \/>\n\t<meta property=\"og:image:height\" content=\"896\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@IFPMA\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.ifpma.org\/publications\/global-regulatory-approaches-to-post-approval-changes-in-biotherapeutic-products\/\",\"url\":\"https:\/\/www.ifpma.org\/publications\/global-regulatory-approaches-to-post-approval-changes-in-biotherapeutic-products\/\",\"name\":\"Global regulatory approaches to post-approval changes in biotherapeutic products | IFPMA\",\"isPartOf\":{\"@id\":\"https:\/\/www.ifpma.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.ifpma.org\/publications\/global-regulatory-approaches-to-post-approval-changes-in-biotherapeutic-products\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.ifpma.org\/publications\/global-regulatory-approaches-to-post-approval-changes-in-biotherapeutic-products\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.ifpma.org\/wp-content\/uploads\/2024\/12\/Copy-of-Publications-Portrait-cover.png\",\"datePublished\":\"2024-12-19T16:17:20+00:00\",\"dateModified\":\"2025-11-04T15:08:46+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.ifpma.org\/publications\/global-regulatory-approaches-to-post-approval-changes-in-biotherapeutic-products\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.ifpma.org\/publications\/global-regulatory-approaches-to-post-approval-changes-in-biotherapeutic-products\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.ifpma.org\/publications\/global-regulatory-approaches-to-post-approval-changes-in-biotherapeutic-products\/#primaryimage\",\"url\":\"https:\/\/www.ifpma.org\/wp-content\/uploads\/2024\/12\/Copy-of-Publications-Portrait-cover.png\",\"contentUrl\":\"https:\/\/www.ifpma.org\/wp-content\/uploads\/2024\/12\/Copy-of-Publications-Portrait-cover.png\",\"width\":634,\"height\":896},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.ifpma.org\/publications\/global-regulatory-approaches-to-post-approval-changes-in-biotherapeutic-products\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.ifpma.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Publications\",\"item\":\"https:\/\/www.ifpma.org\/publications\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Global regulatory approaches to post-approval changes in biotherapeutic products\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.ifpma.org\/#website\",\"url\":\"https:\/\/www.ifpma.org\/\",\"name\":\"IFPMA\",\"description\":\"Innovating to improve health worldwide\",\"publisher\":{\"@id\":\"https:\/\/www.ifpma.org\/#organization\"},\"alternateName\":\"International Federation of Pharmaceutical Manufacturers and Associations\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.ifpma.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.ifpma.org\/#organization\",\"name\":\"IFPMA\",\"alternateName\":\"International Federation of Pharmaceutical Manufacturers and Associations\",\"url\":\"https:\/\/www.ifpma.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.ifpma.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.ifpma.org\/wp-content\/uploads\/2023\/04\/ifpma-logo-landscape-narrow.png\",\"contentUrl\":\"https:\/\/www.ifpma.org\/wp-content\/uploads\/2023\/04\/ifpma-logo-landscape-narrow.png\",\"width\":1379,\"height\":733,\"caption\":\"IFPMA\"},\"image\":{\"@id\":\"https:\/\/www.ifpma.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/IFPMA\/\",\"https:\/\/x.com\/IFPMA\",\"https:\/\/www.linkedin.com\/company\/ifpma\/\",\"https:\/\/www.youtube.com\/user\/ifpma\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Global regulatory approaches to post-approval changes in biotherapeutic products | IFPMA","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ifpma.org\/publications\/global-regulatory-approaches-to-post-approval-changes-in-biotherapeutic-products\/","og_locale":"en_US","og_type":"article","og_title":"Global regulatory approaches to post-approval changes in biotherapeutic products | IFPMA","og_description":"IFPMA worked with Clarivate to study how different countries regulate post-approval changes (PACs) in biotherapeutic products. The research compared PACs guidelines across 21 countries and regions in Latin America (LATAM), Asia-Pacific (APAC), and the Middle East and Africa (MEA) to the World Health Organization (WHO) Guidelines on changes on biotherapeutic products. The findings reveal significant diversity in the level of convergence among countries and with the WHO Reference Guidelines, with a few notable trends.","og_url":"https:\/\/www.ifpma.org\/publications\/global-regulatory-approaches-to-post-approval-changes-in-biotherapeutic-products\/","og_site_name":"IFPMA","article_publisher":"https:\/\/www.facebook.com\/IFPMA\/","article_modified_time":"2025-11-04T15:08:46+00:00","og_image":[{"width":634,"height":896,"url":"https:\/\/www.ifpma.org\/wp-content\/uploads\/2024\/12\/Copy-of-Publications-Portrait-cover.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_site":"@IFPMA","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.ifpma.org\/publications\/global-regulatory-approaches-to-post-approval-changes-in-biotherapeutic-products\/","url":"https:\/\/www.ifpma.org\/publications\/global-regulatory-approaches-to-post-approval-changes-in-biotherapeutic-products\/","name":"Global regulatory approaches to post-approval changes in biotherapeutic products | IFPMA","isPartOf":{"@id":"https:\/\/www.ifpma.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.ifpma.org\/publications\/global-regulatory-approaches-to-post-approval-changes-in-biotherapeutic-products\/#primaryimage"},"image":{"@id":"https:\/\/www.ifpma.org\/publications\/global-regulatory-approaches-to-post-approval-changes-in-biotherapeutic-products\/#primaryimage"},"thumbnailUrl":"https:\/\/www.ifpma.org\/wp-content\/uploads\/2024\/12\/Copy-of-Publications-Portrait-cover.png","datePublished":"2024-12-19T16:17:20+00:00","dateModified":"2025-11-04T15:08:46+00:00","breadcrumb":{"@id":"https:\/\/www.ifpma.org\/publications\/global-regulatory-approaches-to-post-approval-changes-in-biotherapeutic-products\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ifpma.org\/publications\/global-regulatory-approaches-to-post-approval-changes-in-biotherapeutic-products\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ifpma.org\/publications\/global-regulatory-approaches-to-post-approval-changes-in-biotherapeutic-products\/#primaryimage","url":"https:\/\/www.ifpma.org\/wp-content\/uploads\/2024\/12\/Copy-of-Publications-Portrait-cover.png","contentUrl":"https:\/\/www.ifpma.org\/wp-content\/uploads\/2024\/12\/Copy-of-Publications-Portrait-cover.png","width":634,"height":896},{"@type":"BreadcrumbList","@id":"https:\/\/www.ifpma.org\/publications\/global-regulatory-approaches-to-post-approval-changes-in-biotherapeutic-products\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ifpma.org\/"},{"@type":"ListItem","position":2,"name":"Publications","item":"https:\/\/www.ifpma.org\/publications\/"},{"@type":"ListItem","position":3,"name":"Global regulatory approaches to post-approval changes in biotherapeutic products"}]},{"@type":"WebSite","@id":"https:\/\/www.ifpma.org\/#website","url":"https:\/\/www.ifpma.org\/","name":"IFPMA","description":"Innovating to improve health worldwide","publisher":{"@id":"https:\/\/www.ifpma.org\/#organization"},"alternateName":"International Federation of Pharmaceutical Manufacturers and Associations","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ifpma.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.ifpma.org\/#organization","name":"IFPMA","alternateName":"International Federation of Pharmaceutical Manufacturers and Associations","url":"https:\/\/www.ifpma.org\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ifpma.org\/#\/schema\/logo\/image\/","url":"https:\/\/www.ifpma.org\/wp-content\/uploads\/2023\/04\/ifpma-logo-landscape-narrow.png","contentUrl":"https:\/\/www.ifpma.org\/wp-content\/uploads\/2023\/04\/ifpma-logo-landscape-narrow.png","width":1379,"height":733,"caption":"IFPMA"},"image":{"@id":"https:\/\/www.ifpma.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/IFPMA\/","https:\/\/x.com\/IFPMA","https:\/\/www.linkedin.com\/company\/ifpma\/","https:\/\/www.youtube.com\/user\/ifpma"]}]}},"_links":{"self":[{"href":"https:\/\/www.ifpma.org\/wp-json\/wp\/v2\/publications\/16805","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ifpma.org\/wp-json\/wp\/v2\/publications"}],"about":[{"href":"https:\/\/www.ifpma.org\/wp-json\/wp\/v2\/types\/publications"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.ifpma.org\/wp-json\/wp\/v2\/media\/16806"}],"wp:attachment":[{"href":"https:\/\/www.ifpma.org\/wp-json\/wp\/v2\/media?parent=16805"}],"wp:term":[{"taxonomy":"publication_type","embeddable":true,"href":"https:\/\/www.ifpma.org\/wp-json\/wp\/v2\/publication_type?post=16805"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/www.ifpma.org\/wp-json\/wp\/v2\/topic?post=16805"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}